Novo Nordisk, Ozempic

Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for those manufacturers to make safely.
Ozempic and Alzheimer's, 23andMe's crisis, and Novo Nordisk wants a crackdown: Pharma news roundup
A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, the company that popularized consumer genetic testing, could soon be delisted from the Nasdaq.
Novo Nordisk’s Ozempic Linked to Reduced Alzheimer’s Diagnoses
Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
Novo Nordisk just hit a technical red flag with a Death Cross, but its strong fundamentals suggest a potential rebound.
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic,
Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued
Novo Nordisk is among global pharma leaders in the diabetes and weight loss segments. Read why I think NVO stock is a hold.
Ozempic May Reduce the Risk of Alzheimer’s. That’s Huge for Novo Nordisk.
Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.
BioSpace1d
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...
Nvidia Launches Danish Sovereign AI Supercomputer That Novo Nordisk Will Use
Pharmaceutical giant Novo Nordisk plans to use Denmark's first sovereign artificial intelligence supercomputer—powered by ...
FiercePharma2d
Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide
The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo ...
Novo Nordisk's semaglutide could also be effective against Alzheimer's
A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...
Pharma’s race for obesity drugs is still hotting up
The UK’s AstraZeneca, which is working on an oral GLP-1, also views the drugs as part of a combination strategy. In other ...
Drugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says
A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing ...